PTPN22-IN-1 is a potent PTPN22 inhibitor ( IC 50 =1.4 µM; K i =0.50 µM). PTPN22-IN-1 exhibits >7-10 fold selectivity for PTPN22 over similar phosphatases. PTPN22-IN-1 augments antitumor immune responses. From WO2021007491A1 compound L-1. In Vitro PTPN22-IN-1 (Compound L-1) (WT mice; intraperitoneally) significantly reduces MC38 tumor growth. PTPN22-IN-1 (syngeneic immunocompetent model; CT26 in Balb/c mice) shows similar antitumor effects. ?\nAdministration of L-l intraperitoneally at 10 mg/kg yielded an average AUC of 4.55 μM h and C max of 1.1 1 μM (Fig. 9d), which is more than twice of its K i value. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PTPN22-IN-1 (Compound L-1) (WT mice; intraperitoneally) significantly reduces MC38 tumor growth. PTPN22-IN-1 (syngeneic immunocompetent model; CT26 in Balb/c mice) shows similar antitumor effects . ?\nAdministration of L-l intraperitoneally at 10 mg/kg yielded an average AUC of 4.55 μM h and C max of 1.1 1 μM, which is more than twice of its K i value . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid